Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07133659 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Exploring the Efficacy, Safety of a Modified Starting Dosage of Avatrombopag in Immune Throbocytopenia (ITP) - a Pilot Study

Study acronym: Ava dosing
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 21, 2025 (before its estimated July 8, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This is a single-center, open label pilot trial where patients with primary ITP who require second line treatment will be offered avatrombopag at a reduced starting dose, adjusted thereafter according to the response and continued for up to 24 weeks. The study aims to acquire experience on use of avatrombopag and explore the efficacy and safety of lower starting dose of avatrombopag
Trial Details
NCT Number NCT07133659
Lead Sponsor Al-Mustansiriyah University
Conditions
(from sponsor)		 ITP - Immune Thrombocytopenia
Related terms Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov